» Articles » PMID: 26814176

The Adenovirus E4-ORF3 Protein Stimulates SUMOylation of General Transcription Factor TFII-I to Direct Proteasomal Degradation

Overview
Journal mBio
Specialty Microbiology
Date 2016 Jan 28
PMID 26814176
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Modulation of host cell transcription, translation, and posttranslational modification processes is critical for the ability of many viruses to replicate efficiently within host cells. The human adenovirus (Ad) early region 4 open reading frame 3 (E4-ORF3) protein forms unique inclusions throughout the nuclei of infected cells and inhibits the antiviral Mre11-Rad50-Nbs1 DNA repair complex through relocalization. E4-ORF3 also induces SUMOylation of Mre11 and Nbs1. We recently identified additional cellular targets of E4-ORF3 and found that E4-ORF3 stimulates ubiquitin-like modification of 41 cellular proteins involved in a wide variety of processes. Among the proteins most abundantly modified in an E4-ORF3-dependent manner was the general transcription factor II-I (TFII-I). Analysis of Ad-infected cells revealed that E4-ORF3 induces TFII-I relocalization and SUMOylation early during infection. In the present study, we explored the relationship between E4-ORF3 and TFII-I. We found that Ad infection or ectopic E4-ORF3 expression leads to SUMOylation of TFII-I that precedes a rapid decline in TFII-I protein levels. We also show that E4-ORF3 is required for ubiquitination of TFII-I and subsequent proteasomal degradation. This is the first evidence that E4-ORF3 regulates ubiquitination. Interestingly, we found that E4-ORF3 modulation of TFII-I occurs in diverse cell types but only E4-ORF3 of Ad species C regulates TFII-I, providing critical insight into the mechanism by which E4-ORF3 targets TFII-I. Finally, we show that E4-ORF3 stimulates the activity of a TFII-I-repressed viral promoter during infection. Our results characterize a novel mechanism of TFII-I regulation by Ad and highlight how a viral protein can modulate a critical cellular transcription factor during infection.

Importance: Adenovirus has evolved a number of mechanisms to target host signaling pathways in order to optimize the cellular environment during infection. E4-ORF3 is a small viral protein made early during infection, and it is critical for inactivating host antiviral responses. In addition to its ability to capture and reorganize cellular proteins, E4-ORF3 also regulates posttranslational modifications of target proteins, but little is known about the functional consequences of these modifications. We recently identified TFII-I as a novel target of E4-ORF3 that is relocalized into dynamic E4-ORF3 nuclear structures and subjected to E4-ORF3-mediated SUMO modification. Here, we show that TFII-I is targeted by E4-ORF3 for ubiquitination and proteasomal degradation and that E4-ORF3 stimulates gene expression from a TFII-I-repressed viral promoter. Our findings suggest that the specific targeting of TFII-I by E4-ORF3 is a mechanism to inactivate its antiviral properties. These studies provide further insight into how E4-ORF3 functions to counteract host antiviral responses.

Citing Articles

Adenovirus E1B-55K controls SUMO-dependent degradation of antiviral cellular restriction factors.

Ip W, Tatham M, Krohne S, Gruhne J, Melling M, Meyer T J Virol. 2023; 97(11):e0079123.

PMID: 37916833 PMC: 10688335. DOI: 10.1128/jvi.00791-23.


A Tale of Usurpation and Subversion: SUMO-Dependent Integrity of Promyelocytic Leukemia Nuclear Bodies at the Crossroad of Infection and Immunity.

Patra U, Muller S Front Cell Dev Biol. 2021; 9:696234.

PMID: 34513832 PMC: 8430037. DOI: 10.3389/fcell.2021.696234.


Adenovirus targets transcriptional and posttranslational mechanisms to limit gap junction function.

Calhoun P, Phan A, Taylor J, James C, Padget R, Zeitz M FASEB J. 2020; 34(7):9694-9712.

PMID: 32485054 PMC: 7501180. DOI: 10.1096/fj.202000667R.


ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity.

Hofmann S, Mai J, Masser S, Groitl P, Herrmann A, Sternsdorf T Adv Sci (Weinh). 2020; 7(8):1902130.

PMID: 32328411 PMC: 7175289. DOI: 10.1002/advs.201902130.


Adenoviral strategies to overcome innate cellular responses to infection.

Sohn S, Hearing P FEBS Lett. 2019; 593(24):3484-3495.

PMID: 31721176 PMC: 6928427. DOI: 10.1002/1873-3468.13680.


References
1.
Everett R, Boutell C, Hale B . Interplay between viruses and host sumoylation pathways. Nat Rev Microbiol. 2013; 11(6):400-11. DOI: 10.1038/nrmicro3015. View

2.
Evans V, Barker G, Heesom K, Fan J, Bessant C, Matthews D . De novo derivation of proteomes from transcriptomes for transcript and protein identification. Nat Methods. 2012; 9(12):1207-11. PMC: 3581816. DOI: 10.1038/nmeth.2227. View

3.
Leppard K, Emmott E, Cortese M, Rich T . Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis. J Gen Virol. 2008; 90(Pt 1):95-104. DOI: 10.1099/vir.0.005512-0. View

4.
Randow F, Lehner P . Viral avoidance and exploitation of the ubiquitin system. Nat Cell Biol. 2009; 11(5):527-34. DOI: 10.1038/ncb0509-527. View

5.
Tatham M, Rodriguez M, Xirodimas D, Hay R . Detection of protein SUMOylation in vivo. Nat Protoc. 2009; 4(9):1363-71. DOI: 10.1038/nprot.2009.128. View